| Literature DB >> 14578629 |
Masafumi Myoishi1, Satoshi Yasuda, Shunichi Miyazaki, Kazuyuki Ueno, Isao Morii, Kazuhiro Satomi, Yoritaka Otsuka, Atsushi Kawamura, Takashi Kurita, Shiro Kamakura, Hiroshi Nonogi.
Abstract
Excretion in the urine is an important pathway for the elimination of nifekalant hydrochloride (NIF), a novel class III antiarrhythmic agent. Three patients with renal failure were undergoing hemodialysis and receiving NIF for the prevention of ischemia-induced ventricular tachyarrhythmia. Because NIF is not dialyzed, dose adjustment at relatively low concentrations was required, with monitoring of the QT interval.Entities:
Mesh：
Substances：
Year: 2003 PMID： 14578629 DOI： 10.1253/circj.67.898
Source DB: PubMed Journal: Circ J ISSN： 1346-9843 Impact factor: 2.993